Loading organizations...
Based in Taipei City, Taiwan, Elixiron Immunotherapeutics develops precision-targeted immunotherapy drugs for neuroinflammation, autoimmune diseases, oncology, and immunological disorders. The clinical-stage biotechnology company currently operates with a total paid-in capital of 621,180,000 NT$ and successfully closed a $27 million Series A-1 equity financing round in August 2021. This venture capital funding, alongside an additional $1 million research grant awarded by the Alzheimer's Association, directly supports the ongoing advancement of its proprietary clinical assets. The firm's primary lead candidate, an inhibitor known as Enrupatinib, has recently progressed into Phase II clinical trials for the targeted treatment of Alzheimer's disease and vitiligo. The organization's executive leadership team includes executive vice presidents Pandelakis Koni and Carrie Duan, who oversee the company's research and clinical development operations. Elixiron Immunotherapeutics was officially founded in 2017 by Dr. Hung-Kai Chen alongside two other unnamed co-founders.
Elixiron Immunotherapeutics has raised $40.8M across 2 funding rounds.
Elixiron Immunotherapeutics has raised $40.8M in total across 2 funding rounds.
Elixiron Immunotherapeutics has raised $40.8M across 2 funding rounds. Most recently, it raised $13.8M Other Equity in March 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 29, 2024 | $13.8M Venture Round | — | — | Announced |
| Aug 23, 2021 | $27M Series A Plus | Pangu Capital | CDIB Capital Group, Daiwa Corporate Investment, Fubon Ventures, Hong TAI Electric Industrial, Mega International Commercial Bank | Announced |
Elixiron Immunotherapeutics has raised $40.8M in total across 2 funding rounds.
Elixiron Immunotherapeutics's investors include Pangu Capital, CDIB Capital Group, Daiwa Corporate Investment, Fubon Ventures, Hong Tai Electric Industrial, Mega International Commercial Bank.
Elixiron Immunotherapeutics is a clinical-stage biotechnology company developing precision immunotherapies targeting neuroinflammation, autoimmune diseases, and cancer.[1][2][3] Its lead candidates include Enrupatinib (EI-1071), a CSF-1R inhibitor for Alzheimer's disease that modulates brain microglia to reduce neuroinflammation, and Indemakitug, a next-generation anti-IFN-γ antibody for vitiligo addressing immune dysregulation; both are in clinical trials.[1][2] The company serves patients with debilitating conditions like Alzheimer's, vitiligo, idiopathic pulmonary fibrosis, and various cancers, solving unmet needs in neuroinflammation and immune dysregulation through innovative biologics and small molecules.[1][2][3] Elixiron has earned two Alzheimer's Association "Part the Cloud" awards, a $1M grant, orphan drug designation for EI-1071, and two licensing collaborations, while seeking capital to accelerate development.[1][2][3]
Elixiron Immunotherapeutics leverages decades of expertise in immunology, drug discovery, and translational medicine, with headquarters in Taipei, Taiwan, and operations linked to Cambridge, Massachusetts.[1][2][3] While specific founders are not detailed in available sources, the company emerged from advanced platforms like phage display and single human B cell cloning to pioneer therapies for cancer and immunological diseases.[4] Pivotal early moments include securing Alzheimer's Association grants (including $1M in 2020), orphan drug designation from the FDA for EI-1071 in idiopathic pulmonary fibrosis, and two out-licensing agreements, propelling Enrupatinib and Indemakitug into clinical stages.[1][2][3]
Elixiron rides the wave of neuroinflammation-targeted therapies in biotech, a key trend in Alzheimer's and autoimmune treatments amid rising dementia prevalence and precision medicine advances.[1][2] Timing aligns with FDA incentives like orphan designations and grants, plus growing demand for microglia-modulating drugs as traditional Alzheimer's approaches falter.[3] Market forces favoring Elixiron include biotech funding for immunology pipelines and partnerships, positioning it to influence the ecosystem by validating novel targets like CSF-1R and IFN-γ in underserved areas like vitiligo and fibrosis.[1][2][3][5]
Elixiron is poised to advance Enrupatinib and Indemakitug through later-stage trials, potentially delivering blockbusters with additional capital.[1][2] Trends like AI-driven drug discovery and neuroimmunology expansion will shape its path, amplifying influence via more collaborations and regulatory wins. As clinical data emerges, Elixiron could redefine precision immunotherapies for neuroinflammation, fulfilling its mission to translate discoveries into global patient therapies—starting from a clinical-stage biotech with proven momentum.[1][3]
